Abstract 1562: Correlative biomarker analysis of the phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in BRCA wild-type (BRCAwt), platinum-resistant recurrent, high-grade serous ovarian cancer (PR-HGSOC)
Year: 2023
Type: conference-abstract
Source: Cancer Research
Institution: National Cancer Institute
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4362543891